NuNerve

NuNerve is a pre-clinical stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases, with a primary emphasis on Amyotrophic Lateral Sclerosis (ALS). The company's lead program centers on a small molecule Sigma-1 receptor agonist designed to provide neuroprotection and improve motor function in patients. By targeting the Sigma-1 receptor, NuNerve aims to address the underlying cellular stress and protein misfolding associated with motor neuron degeneration. The company was founded based on research from the University of Nebraska Medical Center and is currently advancing its lead candidate through IND-enabling studies.